Navigation Links
First heart patients implanted with next-generation mechanical heart pump
Date:6/2/2009

NEW YORK (May 29, 2009) -- Three patients at NewYork-Presbyterian Hospital/Columbia University Medical Center were among the first in the United States to be implanted with a next-generation artificial heart pump called the DuraHeart Left-Ventricular Assist System. The surgeries took place earlier this year. NewYork-Presbyterian/Columbia is one of only three centers in the U.S. currently enrolling patients in a clinical trial studying the device.

The DuraHeart is designed to sustain patients with severe left-ventricular heart failure while they wait for a heart transplant. Without intervention, they are at risk of death.

The surgeries were led by Dr. Yoshifumi Naka, director of cardiac transplantation at NewYork-Presbyterian Hospital/Columbia University Medical Center and associate professor of surgery at Columbia University College of Physicians and Surgeons. He elected to implant the device without stopping the heart and putting the patient on a heart-lung machine. This "off pump" approach reduces risk for bleeding and stroke associated with putting a patient on bypass.

"In this clinical trial, we hope to show that this device can help patients retain a healthy and meaningful quality of life while awaiting a heart transplant," says Dr. Naka, one of three national co-principal investigators of the DuraHeart trial. "Eventually, the DuraHeart may also prove to be a long-term solution, even for those ineligible for transplantation."

There are fewer than 2,500 hearts transplanted each year in the United States, while 500,000 to 800,000 patients have advanced heart failure; many do not qualify for transplantation due to other health issues. The average wait for a transplant is nine months due to a shortage of donor organs.

In patients with advanced heart failure, their heart isn't strong enough to pump sufficient blood for normal activities, leaving them greatly fatigued and frequently bedridden with difficulty breathing; heart failure is the number one reason for hospitalization. Mechanical heart pumps like the DuraHeart are designed to help the heart pump blood from the left ventricle to the aorta, increasing flow throughout the body. Previous research has shown the approach can help alleviate symptoms and improve survival.

The first left-ventricular assist device, or LVAD, became available in the mid-1980s. Since then, the technology has improved, becoming more compact and with fewer moving parts -- including through clinical research at NewYork-Presbyterian/Columbia leading to the FDA approval of Thoratec's HeartMate and HeartMate II. The DuraHeart is considered a third-generation device, with unique features -- including a paddlewheel-like component called an impeller that is suspended by an electromagnet -- eliminating any bearings or contact points and allowing it to work at slower speeds, potentially reducing device wear and risk for blood cell breakage.


'/>"/>

Contact: Belinda Mager
bem9048@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. Surveyed Psychiatrists and PCPs Expect to Increase Their First-Line Use of SNRIs Over the Next Two Years for the Treatment of Generalized Anxiety Disorder
2. The First High-Performance Sports Water, AquaHydrate, Delivers Cellular Hydration and Electrolytes, Naturally
3. B. Braun Anticipates Becoming First to Deliver FDA Approved 2g Cefazolin
4. The First High Performance Sports Water - AquaHydrate - to Offer Ionic Minerals Through Exclusive Agreement With Natural Foods Pioneer, Trace Minerals Research
5. Streamline Health to Announce First Quarter Fiscal Year 2009 Financial Results on Tuesday, June 9, 2009
6. Ingenious Med Experiences Impressive Growth in First Quarter 2009
7. Quest Diagnostics Introduces First Comprehensive Laboratory Test To Analyze KRAS, NRAS, and BRAF Gene Mutations in Reflex Testing Service
8. Minnesota Health Plans Select IGI and ORBIT(R) to Power First State-Mandated Shift to Standardized, Electronic Data Exchange between Plans and Providers
9. ChemGenexs omacetaxine may provide first viable treatment option for highly resistant form of CML
10. Roshan Announces Expansion of Afghanistans First Telemedicine Project to Bamyan Region
11. PLUS Diagnostics First National Laboratory to Offer Highly Specialized Gastrointestinal Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... , ... December 05, 2016 ... ... interoperability, today announced that the company will provide alerting technology to Central ... been recently awarded $1.7 million in federal funds as the sole sub-recipient ...
(Date:12/5/2016)... ... , ... U.S. Apple Association (USApple) begins the holiday giving season by donating ... for Education: Buy an Apple, Help a Student fundraising campaign. , ... home to their families; solar technology to efficiently process compost; and iPads to enhance ...
(Date:12/5/2016)... ... , ... “Life Will Never Be The Same” is a fictional tale about ... Be The Same” is the creation of published author, Kim T. Briggs, a self-described ... degree in Christian religion and philosophy from Judson University in Elgin, Illinois. Having written ...
(Date:12/5/2016)... ... December 05, 2016 , ... The new knee compression sleeves come ... buy neoprene knee sleeves for lifting and any sport that requires knee ... two main aspects to provide a higher quality knee sleeve performance. Firstly it is ...
(Date:12/5/2016)... ... December 05, 2016 , ... Z-Medica, LLC, a leading developer ... The American College of Surgeons (ACS) to provide basic bleeding control instructor training ... Basic” course is a pilot program that fulfills the intent of the White ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... BOCA RATON, Fla. , Dec. 5, 2016 ... has entered into a multi-product marketing agreement with ... seven (7) injectable products. Under the terms of ... products under its label in the ... approved ANDA,s and one tentatively-approved ANDA. The products ...
(Date:12/5/2016)... and PUNE, India , December 5, ... by Allied Market Research, titled, "Global Cancer Biomarkers Market - ... of cancer biomarkers market is projected to reach $15,737 million ... of 13.3% from 2016 to 2022. Omic technologies segment accounted ... and is expected to maintain its dominance during the forecast ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
Breaking Medicine Technology: